Tisento Therapeutics, Inc.

About Tisento Therapeutics, Inc.

Tisento Therapeutics is a company focused on listening to patients, families, clinicians, and scientific data to drive meaningful innovation in medicine. Their mission is to deliver treatments that address critical needs for those with serious diseases, with a current emphasis on developing solutions for Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like episodes (MELAS).

Products & Services

Zagociguat:An investigational, oral, once-daily, first-in-class, brain-penetrant soluble guanylate cyclase (sGC) stimulator targeting dysregulated pathways in MELAS. It has shown an excellent safety profile, central nervous system exposure, improvements in mitochondrial and neuronal function, and increased brain blood flow in a Phase 2a study.

Specialties

Mitochondrial Diseases MELAS Treatment Soluble Guanylate Cyclase (sGC) Stimulation Clinical Research

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 81000000 MR: - FA: $81 million FAN: 81000000	D: 2023-07-31 FD: 2023-07-31	7 investors

Series A Latest

2023-07-31

$81.0M

7 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Allison Burton

Regulatory Affairs Associate

LinkedIn (Pro only)

J

Jennifer Chickering

Vice President, Program Leadership

LinkedIn (Pro only)

C

Chad Glasser

Vice President, Clinical Research

LinkedIn (Pro only)

S

Sara Hagmeier

Senior Director, Finance & Operations

P

Peter Hecht

Chief Executive Officer

B

Bill Kissel

Vice President of Pharmaceutical Operations

View 13 more team members with Pro

Unlock Full Team Directory

Recent News